1. DETECTION KIT FOR NONINVASIVE FETAL TRISOMY (T21, T18, T13) TEST (COMBINATORIAL PROBE-ANCHOR SYNTHESIS SEQUENCING METHOD)
- Risk class / Clase de Riesgo
- II
- Product type (Spanish)
- REACTIVO DIAGNOSTICO
- Product type (English)
- DIAGNOSTIC REAGENT
- Analysis ID
- d9b8f213a93f9d6dd489cb64103bfb92
- Expire date
- March 01, 2034
- Name (Spanish)
- GENCELL PHARMA SAS
- Name (English)
- GENCELL PHARMA SAS
DETERMINACIÓN DE LOS DIFERENTES ANALITOS RELACIONADOS CON MUESTRAS PROCEDENTES DEL ORGANISMO HUMANO.
DETERMINATION OF THE DIFFERENT ANALYTES RELATED TO SAMPLES FROM THE HUMAN ORGANISM.
Access comprehensive regulatory information for 1. DETECTION KIT FOR NONINVASIVE FETAL TRISOMY (T21, T18, T13) TEST (COMBINATORIAL PROBE-ANCHOR SYNTHESIS SEQUENCING METHOD) (1. DETECTION KIT FOR NONINVASIVE FETAL TRISOMY (T21, T18, T13) TEST (COMBINATORIAL PROBE-ANCHOR SYNTHESIS SEQUENCING METHOD)) in the Colombia medical device market through Pure Global AI's free database. This II medical device is registered under INVIMA analysis ID d9b8f213a93f9d6dd489cb64103bfb92 and manufactured by GENCELL PHARMA SAS. The device was registered on March 01, 2034.
This page provides complete registration details including product type (DIAGNOSTIC REAGENT), authorised information, and regulatory compliance data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.